GLPwatch
Mounjaro for Alzheimer's disease
tirzepatide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCMounjaro (tirzepatide) is not FDA-approved for Alzheimer's disease, and any use for this condition is off-label or investigational; research includes mixed findings, with some studies suggesting potential benefits in animal models or mechanistic pathways, while others report no effect on disease-related pathology or cognitive function.
AI summary of the sources below.
| Drug | Mounjaro (tirzepatide) |
|---|---|
| Condition | Alzheimer's disease |
| Approval status | Investigational / off-label |
| Research papers | 12 |
Mounjaro is not FDA-approved for alzheimer's disease; the research below reflects investigational or off-label study only.
Research on tirzepatide for alzheimer's disease (12)
- Tirzepatide prevents neurodegeneration through multiple molecular pathways.
- Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
- The GLP-1 medicines semaglutide and tirzepatide do not alter disease-related pathology, behaviour or cognitive function in 5XFAD and APP/PS1 mice.
- Tirzepatide administration improves cognitive impairment in HFD mice by regulating the SIRT3-NLRP3 axis.
- Tirzepatide: a novel therapeutic approach for Alzheimer's disease.
- A novel therapeutic prospect: a dual-acting tirzepatide for Alzheimer's disease.
- Impacts of tirzepatide on older patients with diminished β-cell function and dementia.
- Tirzepatide associated autoimmune encephalitis: A case report.
- Tirzepatide mitigates Stroke-Induced Blood-Brain barrier disruption by modulating Claudin-1 and C/EBP-α pathways.
- Tirzepatide mitigates cognitive decline in zebrafish model of type 2 diabetes mellitus induced by high-fat diet.
- Tirzepatide versus semaglutide for the prevention of mild cognitive impairment, dementia, and Alzheimer's disease in type 2 diabetes: A real-world, retrospective cohort study.
- Target trial emulations for tirzepatide, semaglutide and SGLT2-inhibitors for dementia in patients with type 2 diabetes: Real world evidence from a retrospective cohort study.